Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 3/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 3/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18989458 | 0.77 | ATR (0.39) | ATRCYP17A1SREBF2CA12CA1 | |
| SCHEMBL18989493 | 0.76 | ATR (0.38) | ATRCYP17A1SREBF2CA12CA1 | |
| SCHEMBL18990033 | 0.75 | HDAC4 (0.38) | — | |
| SCHEMBL17622060 | 0.73 | ACVRL1 (0.60) | — | |
| SCHEMBL6383413 | 0.73 | SORT1 (0.50) | ATRCYP17A1SREBF2CA12CA1 | |
| SCHEMBL30293080 | 0.73 | SMARCA2 (0.57) | ATRCYP17A1MAPKAPK2CA12CA1 | |
| SCHEMBL16055308 | 0.73 | SMARCA2 (0.57) | ATRCYP17A1MAPKAPK2CA12CA1 | |
| SCHEMBL1501665 | 0.73 | SMARCA2 (0.57) | ATRCYP17A1MAPKAPK2CA12CA1 | |
| SCHEMBL29187149 | 0.72 | AR (0.60) | ATRCYP17A1SREBF2CA12CA1 | |
| SCHEMBL29383469 | 0.72 | AR (0.56) | ATRCYP17A1SREBF2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885BCL2 3918/4885BECN1 2893/4885 |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | ATR 4553/4885BCL2 3043/4885BECN1 2826/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885BCL2 3918/4885BECN1 2893/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885BCL2 3918/4885BECN1 2893/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | ATR 1709/4885BCL2 3918/4885BECN1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.